Cell cycle arrest in metformin treated breast cancer cells ... 7thSpace Interactive (press release), NY - 54 minutes ago In sensitive breast cancer lines, the reduction in cyclin D1 led to release ofsequestered CDK inhibitors, p27Kip1 and p21Cip1, and association of these ...
Source: Google News
Recent News and Articles on the Keywords: cancers + breast + 0.17 Related to the article below (Last Update: 8/7/2008)
NHS Gives Death Sentence to Kidney Cancer Patients The Market Oracle, UK - The research group "Breakthrough Breast Cancer" reported that as many as a third of GP's are failing to refer patients with suspected breast cancer as ...
Breast cancer awareness scheme tears down taboos The National, United Arab Emirates - Volunteers examine a mammography machine in the Breast Cancer Awareness Mobile Clinic. Susaan Bagghil for The National AL RASS, SAUDI ARABIA // The walls ...
Vigue swims for a cure Gloucester Daily Times, USA - "I believe if we can find a cure for breast cancer and help one aspect of cancer, we can then find a result in all types of cancers. ...
Registry for Breast Cancer Thermal Ablation Trials Considered FDA news (subscription), VA - The FDA is asking industry whether it makes sense to set up a registry for feasibility studies of local treatment of small breast cancers using different ...
Improved breast cancer screening for Highlands Inverness Courier, UK - AN improved way of screening for breast cancer that can pick up small tumours at a very early stage is to become the standard in Highland from this week. ...
Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk - MC Pike, DV Spicer, L Dahmoush, MF Press - Epidemiologic Reviews, 1993 - Soc Epidemiolc Res ... Page 7. Cell Proliferation and BreastCancer 23 ... 100 breast epithelium during different
weeks of the normal 0.17 (21n Week of menstrual cycle 2 ...
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 - MC King, JH Marks, JB Mandell - Science, 2003 - sciencemag.org ... Grandmother or aunt, 60, 0.17, 0.03, 0.03, 0.23, 2.5, <10 -6. Proband diagnosed
age <45 years and, any relative with breastcancer, 134, 0.14, 0.06, 0.10, 0.30, ...
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers - TR Rebbeck, AM Levin, A Eisen, C Snyder, P Watson, … - jnci, 1999 - jnci.oxfordjournals.org ... HRT data available, we found that the effect of surgery on subsequent breastcancer
risk was ... women who had no HRT exposure (HR = 0.35; 95% CI = 0.17-0.71) or ...
The Nottingham prognostic index in primary breast cancer - MH Galea, RW Blamey, CE Elston, IO Ellis - Breast Cancer Research and Treatment, 1992 - Springer ... with primary operable breastcancer 1976-1981. Results used to derive the NPI. Factors
Original analysis I z Menopause 0.5 1.5 Tumour size 0.17 2.92 Lymph node ...
Expression of Vascular Endothelial Growth Factor (VEGF) Family Members in Breast Cancer - J Kurebayashi, T Otsuki, H Kunisue, Y Mikami, K … - Cancer Science, 1999 - Blackwell Synergy ... node-positive tumors and -negative tumors (2.04?1.07 and 0.39?0.17, P=0.23 ... detected
in two (33%) out of six inflammatory-type breastcancers (primary tumors ...
CDK4 as a targeted approach to treating aggressive breast cancers
Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective drugs might improve treatment.
A team led by Qunyan Yu, and Peter Sicinski, of Dana-Farber reported that the interaction of a certain mutated oncogene and the newly described growth control flaw is seen in about 10 percent of breast cancers.
The overproduction of a common protein, cyclin D1, hyperstimulates a growth switch, CDK4 kinase, causing it to unleash a virulent proliferation of cancer cells and creating a tumor with a very poor prognosis.
" The development of cancer drugs like Gleevec ( Imatinib ) and Iressa ( Gefitinib ) have shown that it is possible to block the action of kinases," said Sicinski, " so we hope that these findings will stimulate interest in developing drugs to block CDK4 as a targeted approach to treating this very aggressive cancer."
Breast cancers composed of cells that contain both the overactive cyclin D1- CDK4 switch and a mutated cancer-causing gene ErbB-2 ( also known as HER2 ) are extremely difficult to treat.
In one recent study, the seven-year survival rate for women with this subgroup of breast cancers was only about 13 percent.
Clinicians have had some recent success in treating breast cancers with a mutated ErbB-2 gene, which are also referred to as being HER2-positive. The targeted therapy Herceptin ( Trastuzumab ) blocks the mutation, improving the outlook for such patients, though it doesn't work in all cases. Sicinski said that a CDK4 inhibitor might be used in combination with Herceptin to provide further benefit in these patients.
If a drug to block CDK4 proved feasible, Sicinski said, it may be possible to test women's breast tumors for the presence of the overactive kinase, and then treat those patients with the inhibitor.
Cyclin D1 is one of a family of proteins that help regulate a cell's passage through its cycle of rest and growth. Overabundance of cyclin D1 has been observed in many cancers. For a number of years, Sicinski's laboratory has carried out a series of experiments to determine whether the protein has an important normal function, or whether it could be blocked by designer drugs to treat breast cancer without harming the patient.
Previously, mice engineered to lack cyclin D1 were found to be highly resistant to certain breast cancers, and other experiments showed that mice in which the cyclin D1 gene had been inactivated developed into more or less normal adults.
However, said Sicinski, it is difficult to design a drug to neutralize the action of a protein like cyclin D1.
In the most recent experiments, the research team's objective was to determine precisely which of cyclin D1's several different functions was responsible for causing breast cancer.
By creating laboratory mice with different combinations of genes present or missing, the researchers were able to isolate the various cyclin D1 activities. They demonstrated that cyclin D1's ability to activate CDK4 kinase activity is what causes the aggressive cancers, and that this same activity is required for the cancer to continue to grow.
Additional experiments found that bioengineered mice in which cyclin D1 could not activate CDK4 kinase were developmentally normal and highly resistant to ErbB-2-caused breast cancers, demonstrating that blocking CDK4 was not harmful to the mice.
The identification of the cyclin D1-CDK4 kinase pathway is important and could pave the way to new therapies, says Sicinski, adding that while it would be difficult to design a drug to inhibit the action of a protein like cyclin D1, blocking a kinase is significantly easier.
